Research Funding

  • December 1, 1974 - September 29, 2006 - General Clinical Research Center, Co-Investigator. Sponsor: NIH/NCRR, Sponsor Award ID: M01RR000079
  • March 3, 2000 - February 28, 2006 - MOLECULAR MARKERS OF PROGNOSIS IN COLON CANCER, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R01CA084019
  • July 1, 1993 - June 30, 1999 - ROLE OF CYTOKINES IN CANCER PATIENTS UNDERGOING SURGERY, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R29CA052863
  • December 1, 1974 - September 29, 2006 - General Clinical Research Center, Co-Investigator. Sponsor: NIH/NCRR, Sponsor Award ID: M01RR000079

Education

Cornell University, Ithaca, NY, 1966-1967, English
Lawrence University, Appleton, Wisconsin, 1967-1968, Biology
Univ. of Minnesota, Minneapolis, MN, B.A., 1969-1971, Physiology
Grad. School, Univ. of Minnesota, Minneapolis, MN, 1971-1975, Cell Biology
Med. School, Univ. of Minnesota, Minneapolis, MN, M.D., 1976-1980, Medicine

Honors & Awards

  • 1971
    BA magna cum laude
  • 1980
    Alpha Omega Alpha Honorary Medical Society

Selected Publications

  1. Wisneski AD, Jin C, Huang CY, Warren R, Hirose K, Nakakura EK, Corvera CU Synchronous Versus Metachronous Colorectal Liver Metastasis Yields Similar Survival in Modern Era.  View on PubMed
  2. Yu J, Navickas A, Asgharian H, Culbertson B, Fish L, Garcia K, Olegario JP, Dermit M, Dodel M, Hänisch B, Luo Y, Weinberg EM, Dienstmann R, Warren RS, Mardakheh FK, Goodarzi H RBMS1 Suppresses Colon Cancer Metastasis through Targeted Stabilization of Its mRNA Regulon.  View on PubMed
  3. Kasai Y, Mahuron K, Hirose K, Corvera CU, Kim GE, Hope TA, Shih BE, Warren RS, Bergsland EK, Nakakura EK A novel stratification of mesenteric mass involvement as a predictor of challenging mesenteric lymph node dissection by minimally invasive approach for ileal neuroendocrine tumors.  View on PubMed
  4. Kasai Y, Hirose K, Corvera CU, Kim GE, Hope TA, Shih BE, Harun N, Kim MO, Warren RS, Bergsland EK, Nakakura EK Residual tumor volume discriminates prognosis after surgery for neuroendocrine liver metastasis.  View on PubMed
  5. Kasai Y, Mahuron K, Hirose K, Corvera CU, Kim GE, Hope TA, Shih BE, Warren RS, Bergsland EK, Nakakura EK Prognostic impact of a large mesenteric mass >2?cm in ileal neuroendocrine tumors.  View on PubMed
  6. Dienstmann R, Villacampa G, Sveen A, Mason MJ, Niedzwiecki D, Nesbakken A, Moreno V, Warren RS, Lothe RA, Guinney J Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer.  View on PubMed
  7. Donner DB, Nakakura EK, Venook AP, Lenz HJ, Zhang W, Hwang J, Bergsland EK, Lin MH, Toriguchi K, Antonia RJ, Warren RS High thymidylate synthase gene expression predicts poor outcome after resection of hepatocellular carcinoma.  View on PubMed
  8. Gbenedio OM, Bonnans C, Grun D, Wang CY, Hatch AJ, Mahoney MR, Barras D, Matli M, Miao Y, Garcia KC, Tejpar S, Delorenzi M, Venook AP, Nixon AB, Warren RS, Roose JP, Depeille P RasGRP1 is a potential biomarker to stratify anti-EGFR therapy response in colorectal cancer.  View on PubMed
  9. Donner DB, Ruan DT, Toriguchi K, Bergsland EK, Nakakura EK, Lin MH, Antonia RJ, Warren RS Mitogen Inducible Gene-6 Is a Prognostic Marker for Patients with Colorectal Liver Metastases.  View on PubMed
  10. Chamberlain CE, German MS, Yang K, Wang J, VanBrocklin H, Regan M, Shokat KM, Ducker GS, Kim GE, Hann B, Donner DB, Warren RS, Venook AP, Bergsland EK, Lee D, Wang Y, Nakakura EK A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors.  View on PubMed
  11. Rajaram S, Heinrich LE, Gordan JD, Avva J, Bonness KM, Witkiewicz AK, Malter JS, Atreya CE, Warren RS, Wu LF, Altschuler SJ Sampling strategies to capture single-cell heterogeneity.  View on PubMed
  12. Hege KM, Bergsland EK, Fisher GA, Nemunaitis JJ, Warren RS, McArthur JG, Lin AA, Schlom J, June CH, Sherwin SA Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer.  View on PubMed
  13. Niedzwiecki D, Frankel WL, Venook AP, Ye X, Friedman PN, Goldberg RM, Mayer RJ, Colacchio TA, Mulligan JM, Davison TS, O'Brien E, Kerr P, Johnston PG, Kennedy RD, Harkin DP, Schilsky RL, Bertagnolli MM, Warren RS, Innocenti F Reply to L. Casadaban et al.  View on PubMed
  14. Niedzwiecki D, Hasson RM, Lenz HJ, Ye C, Redston M, Ogino S, Fuchs CS, Compton CC, Mayer RJ, Goldberg RM, Colacchio TA, Saltz LB, Warren RS, Bertagnolli MM A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803.  View on PubMed
  15. Niedzwiecki D, Frankel WL, Venook AP, Ye X, Friedman PN, Goldberg RM, Mayer RJ, Colacchio TA, Mulligan JM, Davison TS, O'Brien E, Kerr P, Johnston PG, Kennedy RD, Harkin DP, Schilsky RL, Bertagnolli MM, Warren RS, Innocenti F Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance).  View on PubMed
  16. Depeille P, Warren RS, Roose JP Unexpected insights for anti-EGFR cancer therapy.  View on PubMed
  17. Depeille P, Henricks LM, van de Ven RA, Lemmens E, Wang CY, Matli M, Werb Z, Haigis KM, Donner D, Warren R, Roose JP RasGRP1 opposes proliferative EGFR-SOS1-Ras signals and restricts intestinal epithelial cell growth.  View on PubMed
  18. Shiovitz S, Bertagnolli MM, Renfro LA, Nam E, Foster NR, Dzieciatkowski S, Luo Y, Lao VV, Monnat RJ, Emond MJ, Maizels N, Niedzwiecki D, Goldberg RM, Saltz LB, Venook A, Warren RS, Grady WM CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.  View on PubMed
  19. Sinicrope FA, Mahoney MR, Smyrk TC, Thibodeau SN, Warren RS, Bertagnolli MM, Nelson GD, Goldberg RM, Sargent DJ, Alberts SR Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy.  View on PubMed
  20. Farkas C, Martins CP, Escobar D, Hepp MI, Castro AF, Evan G, Gutiérrez JL, Warren R, Donner DB, Pincheira R Wild type p53 transcriptionally represses the SALL2 transcription factor under genotoxic stress.  View on PubMed

Go to UCSF Profiles, powered by CTSI